Pipeline | Decibel Therapeutics

Program

INDICATION

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

OTOPROTECTION

DB-020

Prevention of Cisplatin Ototoxicity

Program

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-020 Cisplatin Prevention of Cisplatin Ototoxicity

P1b efficacy & safety in cisplatin patients ongoing

GENE THERAPY FOR CONGENITAL DEAFNESS

DB-OTO*

Otoferlin Deficiency

Program

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-OTO* Otoferlin Deficiency

DB-103*

Undisclosed

Program

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-103* Undisclosed

DB-104*

Undisclosed

Program

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-104* Undisclosed

REGENERATIVE MEDICINE: VESTIBULE

DB-201*

Age Related Balance Dysfunction; BVP

Program

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-201* Undisclosed Age Related Balance Dysfunction; BVP

About the Program: Vestibular hair cells (VHCs) are the primary sensory cells that enable us to maintain our sense of balance and stabilize our gaze as we move about the world. Humans lose about half of these cells through the normal aging process. Some, however, lose a much higher percentage, resulting in vision problems (known as oscillopsia) and a devastating loss of balance that limits mobility and increases risk of falling. DB-201 is being explored for its ability to regenerate VHCs and thus restore balance function.

The initial focus of the DB-201 program will be the treatment of bilateral vestibulopathy (BVP), a severe balance disorder which, among other causes, can be a side effect of aminoglycoside antibiotics. We also plan to explore the use of DB-201 as a treatment for age-related balance dysfunction.

DB-202

Age Related Balance Dysfunction; BVP

Program

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-202 Undisclosed Age Related Balance Dysfunction; BVP

Novel Discovery

Age Related Balance Dysfunction

Program

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

Novel Discovery Novel Discovery Age Related Balance Dysfunction

REGENERATIVE MEDICINE: COCHLEA

Novel Discovery

Sensorineural Hearing Loss

Program

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

Novel Discovery Sensorineural Hearing Loss

OTOPROTECTION

Target

INDICATION

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-020

Prevention of Cisplatin Ototoxicity

Target

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-020 Prevention of Cisplatin Ototoxicity

GENE THERAPY FOR CONGENITAL DEAFNESS

Target

INDICATION

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-OTO*

Otoferlin Deficiency

Target

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-OTO* Otoferlin Deficiency

DB-103*

Undisclosed

Target

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-103* Undisclosed

DB-104*

Undisclosed

Target

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

DB-104* Undisclosed

REGENERATIVE MEDICINE: VESTIBULE

Target

INDICATION

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE 1

DB-201*

Age Related Balance Dysfunction; BVP

Target

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE 1

DB-201* Age Related Balance Dysfunction; BVP

DB-202

Age Related Balance Dysfunction; BVP

Target

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE 1

DB-202 Age Related Balance Dysfunction; BVP

Novel Discovery

Age Related Balance Dysfunction

Target

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE 1

Novel Discovery Age Related Balance Dysfunction

REGENERATIVE MEDICINE: COCHLEA

Target

INDICATION

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

Novel Discovery

Sensorineural Hearing Loss

Target

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES

PHASE I

Novel Discovery Sensorineural Hearing Loss

*Currently included in the Decibel Regeneron collaboration.

Learn about our approach